Literature DB >> 35657477

CDC7 as a novel biomarker and druggable target in cancer.

Runze Liu1, Yong Huang2.   

Abstract

Due to the bottlenecks encountered in traditional treatment for tumor, more effective drug targets need to be developed. Cell division cycle 7 kinase plays an important role in DNA replication, DNA repair and recombination signaling pathways. In this review, we first describe recent studies on the role of CDC7 in DNA replication in normal human tissues, and then we integrate new evidence focusing on the important role of CDC7 in replication stress tolerance of tumor cells and its impact on the prognosis of clinical oncology patients. Finally, we comb through the CDC7 inhibitors identified in recent studies as a reference for further research in clinical practice.
© 2022. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).

Entities:  

Keywords:  CDC7; CDC7 inhibitors; Cell cycle; Prognosis; Replication stress

Mesh:

Substances:

Year:  2022        PMID: 35657477     DOI: 10.1007/s12094-022-02853-4

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.340


  47 in total

1.  Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.

Authors:  Arndt Vogel; Shukui Qin; Masatoshi Kudo; Yun Su; Stacie Hudgens; Tatsuya Yamashita; Jung-Hwan Yoon; Laetitia Fartoux; Krzysztof Simon; Carlos López; Max Sung; Kalgi Mody; Tatsuroh Ohtsuka; Toshiyuki Tamai; Lee Bennett; Genevieve Meier; Valery Breder
Journal:  Lancet Gastroenterol Hepatol       Date:  2021-06-01

2.  A novel p53-Cdc7 link induced by genotoxic stress.

Authors:  Hisao Masai
Journal:  Cell Cycle       Date:  2017-03-15       Impact factor: 4.534

Review 3.  Regulation and roles of Cdc7 kinase under replication stress.

Authors:  Masayuki Yamada; Hisao Masai; Jiri Bartek
Journal:  Cell Cycle       Date:  2014-05-19       Impact factor: 4.534

4.  Exploring ex vivo peptideolysis of thymopentin and lipid-based nanocarriers towards oral formulations.

Authors:  Mengyang Liu; Darren Svirskis; Thomas Proft; Jacelyn Loh; Shuo Chen; Dali Kang; Jingyuan Wen
Journal:  Int J Pharm       Date:  2022-08-20       Impact factor: 6.510

Review 5.  Targeting tumor-associated macrophages for cancer immunotherapy.

Authors:  Yongheng Shu; Ping Cheng
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-09-18       Impact factor: 10.680

6.  Clinical Validation of Automatable Gaussian Normalized CBV in Brain Tumor Analysis: Superior Reproducibility and Slightly Better Association with Survival than Current Standard Manual Normal Appearing White Matter Normalization.

Authors:  Lei Qin; Xiang Li; Angie Li; Suchun Cheng; Jinrong Qu; Katherine Reinshagen; Jiani Hu; Nathan Himes; Gao Lu; Xiaoyin Xu; Geoffrey S Young
Journal:  Transl Oncol       Date:  2018-09-11       Impact factor: 4.243

7.  A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.

Authors:  Ronan P McLaughlin; Jichao He; Vera E van der Noord; Jevin Redel; John A Foekens; John W M Martens; Marcel Smid; Yinghui Zhang; Bob van de Water
Journal:  Breast Cancer Res       Date:  2019-07-01       Impact factor: 6.466

8.  Targeting CDC7 sensitizes resistance melanoma cells to BRAFV600E-specific inhibitor by blocking the CDC7/MCM2-7 pathway.

Authors:  Shaimaa A Gad; Hamdy E A Ali; Rofaida Gaballa; Rania M Abdelsalam; Mourad Zerfaoui; Hamed I Ali; Salwa H Salama; Sanaa A Kenawy; Emad Kandil; Zakaria Y Abd Elmageed
Journal:  Sci Rep       Date:  2019-10-02       Impact factor: 4.379

9.  EZH2 Contributes To Cisplatin Resistance In Breast Cancer By Epigenetically Suppressing miR-381 Expression.

Authors:  Dongwei Dou; Xin Ge; Xinxing Wang; Xiaodong Xu; Zhe Zhang; Jingjing Seng; Zhang Cao; Yuanting Gu; Mingli Han
Journal:  Onco Targets Ther       Date:  2019-11-13       Impact factor: 4.147

10.  Silencing of ATG4D suppressed proliferation and enhanced cisplatin-induced apoptosis in hepatocellular carcinoma through Akt/Caspase-3 pathway.

Authors:  Jing-Yuan Zhao; Xiao-Yun Li; Tian-De Liu; Bo Liang; Yong Huang; Wen Li
Journal:  Mol Cell Biochem       Date:  2021-07-27       Impact factor: 3.396

View more
  1 in total

1.  Evaluation of the Synergistic Potential of Simultaneous Pan- or Isoform-Specific BET and SYK Inhibition in B-Cell Lymphoma: An In Vitro Approach.

Authors:  Sina Sender; Ahmad Wael Sultan; Daniel Palmer; Dirk Koczan; Anett Sekora; Julia Beck; Ekkehard Schuetz; Leila Taher; Bertram Brenig; Georg Fuellen; Christian Junghanss; Hugo Murua Escobar
Journal:  Cancers (Basel)       Date:  2022-09-27       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.